joris
Overview

CMPX

Cleared (data check passed)

Compass Therapeutics, Inc.

6 programs · 1 analysed

Company data checked 2026-10-17 Framework v6.2.0

Pipeline

Every program the data service lists for this company, including ones that were stopped

Program BPIQ id Stage & event Catalyst (the big event, as given by the company) Analysed Materiality (how much it matters to the company)
Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) Biliary Tract Cancer 17398 Phase 2/3 Data readout October 24, 2026 exact day given Yes Dominant. The only late-stage asset and the only planned marketing application. Its two 2026 events produced the two largest moves in C.7 (-64.6% and -35.2% over the protocol's event window). With the shares at the cash floor, any re-rating of the company runs through this program.
CTX-8371 Cancer, Solid tumor/s 17481 Phase 1 Data readout Q4 2026 rough period (placeholder), not an exact day No Meaningful. Expansion-cohort data guided for Q4 2026 after an ASCO 2026 poster with responses and no dose-limiting toxicities. With tovecimig's filing in doubt, a larger share of the remaining value sits here. Its Q4 2026 window covers tovecimig's disclosed day: one of the two conflicts that make that program CONTAMINATED.
CTX-10726 (PD-1 x VEGF-A bispecific antibody) Solid tumor/s 18722 Phase 1 Data readout Q4 2026 rough period (placeholder), not an exact day No Meaningful but speculative. First patients dosed in 2026 (NCT07419841, started 2026-05-28); initial data guided for Q4 2026. PD-1 x VEGF bispecifics are a crowded, fashionable class, which makes a signal valuable and a thin one easy to dismiss. The second conflict inside the tovecimig window.
Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) Colorectal cancer 17399 Phase 2 Update no big event No Immaterial. has_catalyst is false. COMPANION-003 did not advance in November 2024; the row now tracks an investigator-sponsored Phase 2 (NCT07662031, Washington University, 25 patients) the 2026-08-06 release says has been initiated. Nothing datable.
CTX-471 +/- KEYTRUDA® (pembrolizumab) Cancer, Small cell lung cancer, Non-small cell lung carcinoma, Melanoma 17478 Phase 2 Initiation no big event No Immaterial. has_catalyst is false. A trial start, not data. The Q3 2026 date has passed with no start announced, and NCT07684170 is registered as not yet recruiting; five guided dates missed.
Tovecimig + CTX-471 (CTX-009 + CTX-471) (Bispecific Agonist Combination) Glioblastoma 20762 Phase 2 Initiation no big event No Immaterial. has_catalyst is false. An investigator-sponsored Phase 1b/2 (NCT07392957, 54 patients) with a 2029 primary completion date.

Attribution and cadence

Whether a share-price move can be tied to each program alone, or could come from another program's news, and whether the program is due for a refresh

Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody
Contaminated Another program's result is due close to this one, so a price move cannot be tied to this event alone.
  • CTX-8371 2026-12-31 · BPIQ id 17481 · not yet analysed (BPIQ data row): overlaps, a date the company has given
  • CTX-10726 (PD-1 x VEGF-A bispecific antibody) 2026-12-31 · BPIQ id 18722 · not yet analysed (BPIQ data row): overlaps, a date the company has given

Readout window opens 2026-10-23. Re-checks done: T-5, T-1 (T-5, T-2 and T-1 mean 5, 2 and 1 months before the window opens).

Locked stock calls

Each call shows the dates it covers, so calls made at the same time can be told apart by event

  1. 2026-10-19 → 2026-10-30 · Opens with the first session of the congress week, covers the Saturday 2026-10-24 talk and the first trading session after it (2026-10-26), and closes before the expected early-November third-quarter results.

    Oral Proffered Paper presentation (abstract 459O) of the complete COMPANION-002 Phase 2/3 dataset, including duration of response, at the ESMO Congress 2026 in Madrid

Price history

Daily closing prices and trading volume, with the dates of our re-checks marked

Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody expected result window: 2026-10-23 to 2026-10-27, most likely 2026-10-24 52-week high $6.88 52-week low $0.82 CMPX close $0.86 on 2026-10-16 $6.88 $0.86 $0.82 Shares traded in the week: 500 · week ending 2021-08-20 Shares traded in the week: 28,900 · week ending 2021-08-27 Shares traded in the week: 83,100 · week ending 2021-09-03 Shares traded in the week: 7,500 · week ending 2021-09-10 Shares traded in the week: 1,600 · week ending 2021-09-17 Shares traded in the week: 7,600 · week ending 2021-09-24 Shares traded in the week: 10,700 · week ending 2021-10-01 Shares traded in the week: 20,200 · week ending 2021-10-08 Shares traded in the week: 23,000 · week ending 2021-10-15 Shares traded in the week: 39,100 · week ending 2021-10-22 Shares traded in the week: 37,600 · week ending 2021-10-29 Shares traded in the week: 1,949,700 · week ending 2021-11-05 Shares traded in the week: 1,301,600 · week ending 2021-11-12 Shares traded in the week: 1,393,000 · week ending 2021-11-19 Shares traded in the week: 1,167,000 · week ending 2021-11-26 Shares traded in the week: 2,597,400 · week ending 2021-12-03 Shares traded in the week: 849,100 · week ending 2021-12-10 Shares traded in the week: 1,799,000 · week ending 2021-12-17 Shares traded in the week: 1,061,000 · week ending 2021-12-23 Shares traded in the week: 546,200 · week ending 2021-12-31 Shares traded in the week: 397,000 · week ending 2022-01-07 Shares traded in the week: 438,300 · week ending 2022-01-14 Shares traded in the week: 463,900 · week ending 2022-01-21 Shares traded in the week: 713,900 · week ending 2022-01-28 Shares traded in the week: 1,455,500 · week ending 2022-02-04 Shares traded in the week: 534,500 · week ending 2022-02-11 Shares traded in the week: 672,800 · week ending 2022-02-18 Shares traded in the week: 582,200 · week ending 2022-02-25 Shares traded in the week: 737,000 · week ending 2022-03-04 Shares traded in the week: 769,400 · week ending 2022-03-11 Shares traded in the week: 1,247,100 · week ending 2022-03-18 Shares traded in the week: 490,600 · week ending 2022-03-25 Shares traded in the week: 1,732,600 · week ending 2022-04-01 Shares traded in the week: 897,400 · week ending 2022-04-08 Shares traded in the week: 371,600 · week ending 2022-04-14 Shares traded in the week: 377,600 · week ending 2022-04-22 Shares traded in the week: 275,400 · week ending 2022-04-29 Shares traded in the week: 3,291,700 · week ending 2022-05-06 Shares traded in the week: 1,408,800 · week ending 2022-05-13 Shares traded in the week: 628,700 · week ending 2022-05-20 Shares traded in the week: 1,146,800 · week ending 2022-05-27 Shares traded in the week: 620,700 · week ending 2022-06-03 Shares traded in the week: 566,700 · week ending 2022-06-10 Shares traded in the week: 305,700 · week ending 2022-06-17 Shares traded in the week: 649,200 · week ending 2022-06-24 Shares traded in the week: 194,500 · week ending 2022-07-01 Shares traded in the week: 2,826,300 · week ending 2022-07-08 Shares traded in the week: 440,500 · week ending 2022-07-15 Shares traded in the week: 1,048,500 · week ending 2022-07-22 Shares traded in the week: 144,500 · week ending 2022-07-29 Shares traded in the week: 210,500 · week ending 2022-08-05 Shares traded in the week: 397,700 · week ending 2022-08-12 Shares traded in the week: 260,700 · week ending 2022-08-19 Shares traded in the week: 316,900 · week ending 2022-08-26 Shares traded in the week: 322,700 · week ending 2022-09-02 Shares traded in the week: 1,524,000 · week ending 2022-09-09 Shares traded in the week: 3,840,700 · week ending 2022-09-16 Shares traded in the week: 783,500 · week ending 2022-09-23 Shares traded in the week: 1,531,400 · week ending 2022-09-30 Shares traded in the week: 379,300 · week ending 2022-10-07 Shares traded in the week: 761,400 · week ending 2022-10-14 Shares traded in the week: 329,100 · week ending 2022-10-21 Shares traded in the week: 274,000 · week ending 2022-10-28 Shares traded in the week: 552,400 · week ending 2022-11-04 Shares traded in the week: 577,100 · week ending 2022-11-11 Shares traded in the week: 848,300 · week ending 2022-11-18 Shares traded in the week: 234,300 · week ending 2022-11-25 Shares traded in the week: 676,100 · week ending 2022-12-02 Shares traded in the week: 717,700 · week ending 2022-12-09 Shares traded in the week: 2,056,000 · week ending 2022-12-16 Shares traded in the week: 2,301,300 · week ending 2022-12-23 Shares traded in the week: 960,400 · week ending 2022-12-30 Shares traded in the week: 634,900 · week ending 2023-01-06 Shares traded in the week: 846,900 · week ending 2023-01-13 Shares traded in the week: 2,054,600 · week ending 2023-01-20 Shares traded in the week: 3,032,100 · week ending 2023-01-27 Shares traded in the week: 3,213,500 · week ending 2023-02-03 Shares traded in the week: 1,993,100 · week ending 2023-02-10 Shares traded in the week: 2,112,700 · week ending 2023-02-17 Shares traded in the week: 1,257,700 · week ending 2023-02-24 Shares traded in the week: 1,999,700 · week ending 2023-03-03 Shares traded in the week: 1,572,800 · week ending 2023-03-10 Shares traded in the week: 1,678,500 · week ending 2023-03-17 Shares traded in the week: 1,317,000 · week ending 2023-03-24 Shares traded in the week: 1,076,800 · week ending 2023-03-31 Shares traded in the week: 3,018,400 · week ending 2023-04-06 Shares traded in the week: 2,992,900 · week ending 2023-04-14 Shares traded in the week: 1,379,900 · week ending 2023-04-21 Shares traded in the week: 1,402,800 · week ending 2023-04-28 Shares traded in the week: 1,295,700 · week ending 2023-05-05 Shares traded in the week: 1,266,900 · week ending 2023-05-12 Shares traded in the week: 1,022,900 · week ending 2023-05-19 Shares traded in the week: 2,094,200 · week ending 2023-05-26 Shares traded in the week: 1,633,700 · week ending 2023-06-02 Shares traded in the week: 1,382,900 · week ending 2023-06-09 Shares traded in the week: 2,064,200 · week ending 2023-06-16 Shares traded in the week: 14,442,200 · week ending 2023-06-23 Shares traded in the week: 3,596,500 · week ending 2023-06-30 Shares traded in the week: 1,932,700 · week ending 2023-07-07 Shares traded in the week: 1,847,300 · week ending 2023-07-14 Shares traded in the week: 2,007,300 · week ending 2023-07-21 Shares traded in the week: 1,704,400 · week ending 2023-07-28 Shares traded in the week: 1,499,000 · week ending 2023-08-04 Shares traded in the week: 1,362,800 · week ending 2023-08-11 Shares traded in the week: 944,500 · week ending 2023-08-18 Shares traded in the week: 697,200 · week ending 2023-08-25 Shares traded in the week: 641,300 · week ending 2023-09-01 Shares traded in the week: 740,700 · week ending 2023-09-08 Shares traded in the week: 1,259,900 · week ending 2023-09-15 Shares traded in the week: 1,211,200 · week ending 2023-09-22 Shares traded in the week: 1,072,300 · week ending 2023-09-29 Shares traded in the week: 808,700 · week ending 2023-10-06 Shares traded in the week: 1,862,300 · week ending 2023-10-13 Shares traded in the week: 2,138,800 · week ending 2023-10-20 Shares traded in the week: 966,700 · week ending 2023-10-27 Shares traded in the week: 956,800 · week ending 2023-11-03 Shares traded in the week: 776,700 · week ending 2023-11-10 Shares traded in the week: 4,133,300 · week ending 2023-11-17 Shares traded in the week: 827,700 · week ending 2023-11-24 Shares traded in the week: 2,687,900 · week ending 2023-12-01 Shares traded in the week: 1,314,100 · week ending 2023-12-08 Shares traded in the week: 3,039,300 · week ending 2023-12-15 Shares traded in the week: 2,128,800 · week ending 2023-12-22 Shares traded in the week: 2,184,100 · week ending 2023-12-29 Shares traded in the week: 2,059,200 · week ending 2024-01-05 Shares traded in the week: 8,885,600 · week ending 2024-01-12 Shares traded in the week: 1,507,600 · week ending 2024-01-19 Shares traded in the week: 1,854,000 · week ending 2024-01-26 Shares traded in the week: 1,566,600 · week ending 2024-02-02 Shares traded in the week: 2,132,000 · week ending 2024-02-09 Shares traded in the week: 1,945,800 · week ending 2024-02-16 Shares traded in the week: 732,800 · week ending 2024-02-23 Shares traded in the week: 3,767,000 · week ending 2024-03-01 Shares traded in the week: 1,228,700 · week ending 2024-03-08 Shares traded in the week: 2,210,700 · week ending 2024-03-15 Shares traded in the week: 2,310,200 · week ending 2024-03-22 Shares traded in the week: 647,700 · week ending 2024-03-28 Shares traded in the week: 1,099,900 · week ending 2024-04-05 Shares traded in the week: 3,707,000 · week ending 2024-04-12 Shares traded in the week: 1,437,200 · week ending 2024-04-19 Shares traded in the week: 860,700 · week ending 2024-04-26 Shares traded in the week: 1,399,100 · week ending 2024-05-03 Shares traded in the week: 1,054,200 · week ending 2024-05-10 Shares traded in the week: 1,796,900 · week ending 2024-05-17 Shares traded in the week: 616,300 · week ending 2024-05-24 Shares traded in the week: 729,100 · week ending 2024-05-31 Shares traded in the week: 1,469,400 · week ending 2024-06-07 Shares traded in the week: 1,960,200 · week ending 2024-06-14 Shares traded in the week: 2,469,600 · week ending 2024-06-21 Shares traded in the week: 3,500,300 · week ending 2024-06-28 Shares traded in the week: 1,528,200 · week ending 2024-07-05 Shares traded in the week: 1,110,000 · week ending 2024-07-12 Shares traded in the week: 1,809,300 · week ending 2024-07-19 Shares traded in the week: 1,739,700 · week ending 2024-07-26 Shares traded in the week: 3,250,900 · week ending 2024-08-02 Shares traded in the week: 2,293,700 · week ending 2024-08-09 Shares traded in the week: 2,071,700 · week ending 2024-08-16 Shares traded in the week: 974,000 · week ending 2024-08-23 Shares traded in the week: 2,505,900 · week ending 2024-08-30 Shares traded in the week: 2,467,900 · week ending 2024-09-06 Shares traded in the week: 1,286,900 · week ending 2024-09-13 Shares traded in the week: 2,951,700 · week ending 2024-09-20 Shares traded in the week: 2,027,400 · week ending 2024-09-27 Shares traded in the week: 2,386,400 · week ending 2024-10-04 Shares traded in the week: 2,041,600 · week ending 2024-10-11 Shares traded in the week: 3,641,700 · week ending 2024-10-18 Shares traded in the week: 1,904,900 · week ending 2024-10-25 Shares traded in the week: 1,936,900 · week ending 2024-11-01 Shares traded in the week: 3,046,800 · week ending 2024-11-08 Shares traded in the week: 3,376,600 · week ending 2024-11-15 Shares traded in the week: 2,277,600 · week ending 2024-11-22 Shares traded in the week: 2,192,500 · week ending 2024-11-29 Shares traded in the week: 2,492,900 · week ending 2024-12-06 Shares traded in the week: 1,736,000 · week ending 2024-12-13 Shares traded in the week: 2,052,900 · week ending 2024-12-20 Shares traded in the week: 1,172,900 · week ending 2024-12-27 Shares traded in the week: 1,507,300 · week ending 2025-01-03 Shares traded in the week: 27,795,400 · week ending 2025-01-10 Shares traded in the week: 11,499,700 · week ending 2025-01-17 Shares traded in the week: 6,436,000 · week ending 2025-01-24 Shares traded in the week: 9,703,900 · week ending 2025-01-31 Shares traded in the week: 5,332,400 · week ending 2025-02-07 Shares traded in the week: 6,021,800 · week ending 2025-02-14 Shares traded in the week: 4,546,100 · week ending 2025-02-21 Shares traded in the week: 3,855,900 · week ending 2025-02-28 Shares traded in the week: 3,443,800 · week ending 2025-03-07 Shares traded in the week: 4,521,500 · week ending 2025-03-14 Shares traded in the week: 4,474,700 · week ending 2025-03-21 Shares traded in the week: 4,438,800 · week ending 2025-03-28 Shares traded in the week: 33,627,500 · week ending 2025-04-04 Shares traded in the week: 13,508,600 · week ending 2025-04-11 Shares traded in the week: 2,421,700 · week ending 2025-04-17 Shares traded in the week: 4,107,000 · week ending 2025-04-25 Shares traded in the week: 3,073,800 · week ending 2025-05-02 Shares traded in the week: 5,634,000 · week ending 2025-05-09 Shares traded in the week: 5,330,000 · week ending 2025-05-16 Shares traded in the week: 2,348,400 · week ending 2025-05-23 Shares traded in the week: 2,036,500 · week ending 2025-05-30 Shares traded in the week: 5,706,800 · week ending 2025-06-06 Shares traded in the week: 4,053,900 · week ending 2025-06-13 Shares traded in the week: 3,394,200 · week ending 2025-06-20 Shares traded in the week: 5,732,700 · week ending 2025-06-27 Shares traded in the week: 2,631,300 · week ending 2025-07-03 Shares traded in the week: 3,369,700 · week ending 2025-07-11 Shares traded in the week: 4,648,300 · week ending 2025-07-18 Shares traded in the week: 3,691,600 · week ending 2025-07-25 Shares traded in the week: 3,372,100 · week ending 2025-08-01 Shares traded in the week: 4,012,300 · week ending 2025-08-08 Shares traded in the week: 14,992,200 · week ending 2025-08-15 Shares traded in the week: 5,895,200 · week ending 2025-08-22 Shares traded in the week: 4,421,200 · week ending 2025-08-29 Shares traded in the week: 2,406,500 · week ending 2025-09-05 Shares traded in the week: 5,580,300 · week ending 2025-09-12 Shares traded in the week: 10,283,500 · week ending 2025-09-19 Shares traded in the week: 7,279,600 · week ending 2025-09-26 Shares traded in the week: 9,525,000 · week ending 2025-10-03 Shares traded in the week: 9,814,600 · week ending 2025-10-10 Shares traded in the week: 7,613,500 · week ending 2025-10-17 Shares traded in the week: 11,376,900 · week ending 2025-10-24 Shares traded in the week: 7,064,000 · week ending 2025-10-31 Shares traded in the week: 9,700,100 · week ending 2025-11-07 Shares traded in the week: 12,038,100 · week ending 2025-11-14 Shares traded in the week: 9,360,100 · week ending 2025-11-21 Shares traded in the week: 9,757,300 · week ending 2025-11-28 Shares traded in the week: 9,781,600 · week ending 2025-12-05 Shares traded in the week: 7,348,900 · week ending 2025-12-12 Shares traded in the week: 15,001,400 · week ending 2025-12-19 Shares traded in the week: 4,481,700 · week ending 2025-12-26 Shares traded in the week: 5,628,500 · week ending 2026-01-02 Shares traded in the week: 13,232,800 · week ending 2026-01-09 Shares traded in the week: 16,990,700 · week ending 2026-01-16 Shares traded in the week: 8,932,500 · week ending 2026-01-23 Shares traded in the week: 11,709,500 · week ending 2026-01-30 Shares traded in the week: 11,625,100 · week ending 2026-02-06 Shares traded in the week: 8,406,000 · week ending 2026-02-13 Shares traded in the week: 5,571,400 · week ending 2026-02-20 Shares traded in the week: 12,512,300 · week ending 2026-02-27 Shares traded in the week: 12,203,700 · week ending 2026-03-06 Shares traded in the week: 8,122,900 · week ending 2026-03-13 Shares traded in the week: 13,095,200 · week ending 2026-03-20 Shares traded in the week: 7,534,200 · week ending 2026-03-27 Shares traded in the week: 10,743,700 · week ending 2026-04-02 Shares traded in the week: 13,726,100 · week ending 2026-04-10 Shares traded in the week: 19,934,500 · week ending 2026-04-17 Shares traded in the week: 13,484,700 · week ending 2026-04-24 Shares traded in the week: 245,468,300 · week ending 2026-05-01 Shares traded in the week: 48,140,100 · week ending 2026-05-08 Shares traded in the week: 25,860,300 · week ending 2026-05-15 Shares traded in the week: 24,656,200 · week ending 2026-05-22 Shares traded in the week: 22,330,200 · week ending 2026-05-29 Shares traded in the week: 22,031,400 · week ending 2026-06-05 Shares traded in the week: 13,747,400 · week ending 2026-06-12 Shares traded in the week: 17,728,500 · week ending 2026-06-18 Shares traded in the week: 19,758,600 · week ending 2026-06-26 Shares traded in the week: 12,038,300 · week ending 2026-07-02 Shares traded in the week: 14,346,300 · week ending 2026-07-10 Shares traded in the week: 9,481,300 · week ending 2026-07-17 Shares traded in the week: 9,155,300 · week ending 2026-07-24 Shares traded in the week: 14,277,700 · week ending 2026-07-31 Shares traded in the week: 21,331,000 · week ending 2026-08-07 Shares traded in the week: 20,116,200 · week ending 2026-08-14 Shares traded in the week: 13,406,400 · week ending 2026-08-21 Shares traded in the week: 9,217,400 · week ending 2026-08-28 Shares traded in the week: 12,665,800 · week ending 2026-09-04 Shares traded in the week: 12,404,900 · week ending 2026-09-11 Shares traded in the week: 17,685,400 · week ending 2026-09-18 Shares traded in the week: 45,935,000 · week ending 2026-09-25 Shares traded in the week: 43,682,000 · week ending 2026-10-02 Shares traded in the week: 36,615,100 · week ending 2026-10-09 Shares traded in the week: 18,577,300 · week ending 2026-10-16 2022 2023 2024 2025 2026 Prediction locked on 2026-08-19 · closing price $2.48
Yahoo Finance · daily closing prices · saved 2026-10-17 · expected result window 2026-10-23 to 2026-10-27 View live chart

Market snapshot

What the company is worth and what it owns and owes, on the date its data was checked

Spot
$0.86
Spot As Of
2026-10-16
Spot Kind
settled close of Friday 2026-10-16, read from data/prices/CMPX.json via lib/prices.mjs after a fetch on 2026-10-17; matches BPIQ last_price and Yahoo's daily close (not an intraday snapshot)
Previous Close
0.897
Shares Outstanding
180,087,915
Shares Outstanding As Of
2026-07-28
Shares Outstanding Source
EDGAR XBRL dei:EntityCommonStockSharesOutstanding, 10-Q filed 2026-08-06
Pre Funded Warrants
6,710,000
Economic Share Count
186,797,915
Economic Share Count Note
180,087,915 common shares plus 6,710,000 pre-funded warrants (10-Q filed 2026-08-06). No option is in the money at $0.86: 23,650,088 options at a $3.87 weighted average exercise price, and 200,000 inducement options struck at $0.86. 1,606,250 unvested RSUs are not options and are excluded. The 5.10.3 record divided by the reported count and missed the pre-funded warrants.
Market Cap
$154,875.61B
Market Cap Note
180,087,915 filed shares x $0.86. BPIQ market_cap $154,875,616 agrees on this sweep.
Enterprise Value
-25,003,393
Enterprise Value Note
Market cap less $179.879M cash and marketable securities at 2026-06-30, no debt. Against an estimated 2026-09-30 cash of $165.1M (extrapolated at the second-quarter burn, not reported) it is about -$10.3M. BPIQ enterprise_value $40,456,860 implies subtracting $114.4M, which matches no reported cash figure, and is not used.
Cash
$179,879B
Cash Note
Cash and equivalents $35.453M plus marketable securities $144.426M (EDGAR XBRL, 10-Q filed 2026-08-06).
Quarterly Burn
$14,738B
Quarterly Burn Note
Second-quarter 2026 net cash used in operating activities: -$32.007M for the half less -$17.269M for the first quarter (EDGAR XBRL).
Monthly Burn
$4,912.67B
Runway Company Stated
into 2028
Runway Company Stated As Of
2026-08-06
Runway Recomputed Months
36.6
Runway Note
The company's guidance implies a higher burn than the second-quarter rate and is the one to use. It was not restated after the 2026-09-22 FDA feedback.
Debt
0
Debt Note
No debt concept in EDGAR XBRL companyfacts; total liabilities $24.124M at 2026-06-30, mostly accrued expenses and an office lease.
Fifty Two Week High
$6.88
Fifty Two Week High Date
2026-02-03
Fifty Two Week Low
$0.82
Fifty Two Week Low Date
2026-10-14
Position In 52w Range
0.6%
Position In 52w Range Note
lib/prices.mjs range52w and positionInRange as of 2026-10-16, off the cache's own last close.
Multiple Off 52w Low
$1.05
Listing Compliance
Nasdaq Capital Market. Closes below $1 on 11 of 12 sessions since 2026-10-01; the current run began 2026-10-08 (seven business days to 2026-10-16), so a 30-business-day minimum-bid deficiency notice could not arrive before about 2026-11-19. No 8-K item 3.01 and no reverse-split proposal on EDGAR; the June 2026 annual meeting voted on directors, auditor and pay only. Per-share figures are on the current share count.
Atm Capacity Usd
100,000,000
Atm Note
Sales agreement with Leerink Partners and Cantor Fitzgerald under the $400M S-3 (filed 2025-12-30, effective 2026-01-07); no sales through 2026-06-30.

Ownership and flow

Who holds it, and who has been buying

Insider Pct
12.5%
Institutional Pct
88.6%
Ownership Note
The two figures sum above 100% and the payload does not reconcile them, so no retail residual is derived.
Short Interest Shares
40,357,710
Short Interest Settlement Date
2026-09-30
Short Interest Pct Of Shares Outstanding
22.4%
Short Interest Pct Of Estimated Float
25.6%
Estimated Float Shares
157,636,355
Days To Cover
6.26
Avg Daily Volume Shares
6,449,901
Short Interest Source
FINRA consolidatedShortInterest, settlement 2026-09-30, divided by the EDGAR-filed share count and by the non-affiliate float (shares less the 12.467% insider holding)
Short Interest Trend
39,874,250 (2026-07-31), 40,197,938 (2026-08-14), 40,788,891 (2026-08-31), 41,647,512 (2026-09-15), 40,357,710 (2026-09-30). Days to cover fell from 15.99 to 6.26 because volume tripled after the FDA news, not because shorts closed.
Bpiq Short Float Rejected
0.305
Insider Flow
Chief accounting officer Neil Lerner bought 2,500 shares at $1.14 (2026-09-24) and 20,000 at $0.92 (2026-10-01), transaction code P, about $21,250 in total, holding 420,000 shares after. No other Form 4 since 2026-04-30. Read from EDGAR; the BPIQ insider connector returned no rows on three attempts.
Largest Holders 13f 2026 06 30
Tang Capital 17,990,782; OrbiMed 15,219,994; Vivo 7,757,060; Palo Alto Investors 5,831,813; ADAR1 122,132; Ikarian 18,000 (BPIQ block labelled 2026Q3, confirmed as 2026-06-30 holdings).

Options chain

Whether the chain can price an event at all

Readable
No
Spot
$0.86
Nearest Strike Below
0.5
Nearest Strike Above
1
Expiry Nearest Catalyst
2026-11-20
Atm Straddle Note
Not computable: no strike at spot. The $1.00 straddle on 2026-11-20 costs $0.45 at mid prices (52% of spot), $0.25 at the bid (29%) and $0.65 at the ask (76%). That is not a price.
Front Iv
Call 1.00 2026 11 20
2.532
Put 1.00 2026 11 20
1.244
Open Interest
Call 1.00 2026 11 20
2,700
Put 1.00 2026 11 20
1,334
Put 1.00 2027 01 15
60,014
Call 3.00 2026 11 20
23,664
Notable
60,014 contracts of the January 2027 $1.00 put are open, covering about 6 million shares; 23,664 of the November $3.00 call remain from the August speculation.
Liquidity Confidence
low

Past catalyst reactions

Cross-checked against the press feed

Rows
Row 1
Date
2026-09-22
Event
FDA recommended a survival trial before a BLA
Intraday Pct
-0.8%
Open Gap Pct
-31.3%
Event Window Pct
-35.2%
Close To Close Pct
-31.9%
Read
Regulatory and clean. The gap is the move; the shares kept falling for nine sessions and have stayed below $1.
Row 2
Date
2026-04-27
Event
COMPANION-002 secondary endpoints: PFS met, OS missed
Intraday Pct
1.1%
Open Gap Pct
-64.8%
Event Window Pct
-64.6%
Close To Close Pct
-64.4%
Read
The gap is the move; confirmed by the cache.
Row 3
Date
2025-04-21
Event
First patient dosed, investigator-sponsored first-line trial
Intraday Pct
8.7%
Open Gap Pct
-1.7%
Event Window Pct
9%
Close To Close Pct
1.7%
Read
Administrative.
Row 4
Date
2025-04-01
Event
COMPANION-002 met its primary endpoint (ORR)
Intraday Pct
49.7%
Open Gap Pct
-1.6%
Event Window Pct
1%
Close To Close Pct
17.9%
Read
Named correction: the +49.73% does not reproduce from the cache; the event-window move was +1.0% because the next session gave back the gain.
Row 5
Date
2024-11-08
Event
CTX-471 Phase 1 biomarker data at SITC
Intraday Pct
4.3%
Open Gap Pct
1.6%
Event Window Pct
0.8%
Close To Close Pct
-2.2%
Read
Nearest comparable in kind: a congress presentation of data already described.
Row 6
Date
2024-08-12
Event
COMPANION-003 colorectal Phase 2 data with Q2 results
Intraday Pct
7.1%
Open Gap Pct
2.8%
Event Window Pct
11%
Close To Close Pct
3.7%
Read
Bundled with earnings; not cleanly attributable.
Row 7
Date
2024-04-16
Event
First patient dosed, CTX-8371 Phase 1
Intraday Pct
8.9%
Open Gap Pct
0%
Event Window Pct
-3.1%
Close To Close Pct
-0.6%
Read
Administrative.
Row 8
Date
2024-04-09
Event
Preclinical CTX-009 + CTX-471 data at AACR
Intraday Pct
8.3%
Open Gap Pct
-0.6%
Event Window Pct
-3.8%
Close To Close Pct
-1.8%
Read
Preclinical; third-party sourced.

Delivery Record

Met
COMPANION-002 enrolment completed 2024-08-06, CTX-10726 IND guided Q4 2025, cleared by 2026-03-05, CTX-8371 Phase 1 data guided H1 2026, ASCO poster May 2026, FDA feedback guided Q3 2026, announced 2026-09-22, ESMO slot announced 2026-07-17 for 2026-10-24, unchanged
Missed Or Moved
COMPANION-002 topline guided by end of Q1 2025, reported 2025-04-01, OS data guided Q1 2026, reported 2026-04-27, BLA guided H2 2026, not filed; FDA recommends a survival trial first; Q1 2027 target reported by secondary sources only, CTX-471 Phase 2 start missed five guided dates; NCT07684170 not yet recruiting on 2026-10-17, CTX-10726 first patient guided Q1 2026, registry start 2026-05-28
Manufacturing
No owned manufacturing; unnamed third-party CDMOs (10-K for 2025). $7.5M accrued manufacturing expense mostly for tovecimig at 2026-06-30, including registration and validation batches (10-Q).
Launch Capability
No launched product, no sales force; 39 employees at 2025-12-31; Chief Commercial Officer hired 2026-01-05.
Partnerships
ABL Bio in-licence (Nov 2018; global ex-South Korea; tiered single-digit royalties; up to $96M development/regulatory and $303M commercial milestones in oncology); Handok holds South Korea; Elpiscience China out-licence ($1M milestone in 2024, 15% to ABL Bio); Adimab (2014); investigator-sponsored trials at MD Anderson and Washington University.

Company data-quality flags

  • BPIQ market_cap and max_52_week_position reconcile on this sweep because last price equals last close on a Saturday; the 2026-08-19 previous-close failure is kept as history and is not shown fixed.
  • BPIQ enterprise_value $40,456,860 implies subtracting $114.4M, which matches no reported cash figure (2025-12-31 $208.9M, 2026-03-31 $194.7M, 2026-06-30 $179.9M). Recomputed.
  • BPIQ historical-catalyst move fields do not reproduce from the price cache on most CMPX rows; the 2025-04-01 +49.73% matches no open-to-close, close-to-close or low-to-close move. C.7 uses the cache event window.
  • data/prices/CMPX.json froze an intraday bar on 2026-08-19 (close $2.42 on 1,160,393 shares) against Yahoo's settled $2.48 on 3,903,300 shares. Outside this lane; reported, not corrected. The 2026-10-16 bar used for spot matches Yahoo's settled figures.
  • fetch_company_insider_transactions returned zero rows on three attempts while two Form 4s exist (2026-09-25, 2026-10-02); the connector-wide empty-result bug now fires on CMPX, where it returned 113 rows on 2026-08-19.
  • 13F block labels are filing quarters, now confirmed against the cache: $2.19, $5.29 and $5.37 equal the 2026-06-30, 2026-03-31 and 2025-12-31 closes.
  • BPIQ short_float 0.30476 (dated 2026-09-30) disagrees with FINRA (22.4% of shares outstanding, 25.6% of float). The 5.10.3 suggestion that rising short interest explained the gap is withdrawn: FINRA's 2026-07-31 settlement shows 39,874,250 shares (22.1%).
  • The BPIQ note field is a dated slip log on four of six rows; CTX-471's Phase 2 start has missed five guided dates.
  • A 'Revenue ($25.25M)' figure in third-party 10-Q summaries stays rejected under 01-rules.md rule 6; it is the quarterly net loss mislabelled.
  • Analyst targets conflict and none is a scenario anchor under 6.2.0 (rule 30). Post-2026-09-22: Wedbush $1 (from $5), Guggenheim $4, H.C. Wainwright $12 (from $24), all secondary.
  • Two GlobeNewswire originals returned HTTP 403 (2026-09-22, 2026-10-14); the first was read from its SEC copy, the second rests on a secondary reproduction.

Company document

Background on the company in plain text. Each claim is tagged with the kind of evidence behind it.

CMPX — Compass Therapeutics, Inc.

Company context · prepared 2026-10-17 · company sweep 2026-10-17 · USD · framework v6.2.0

How to read this. Written for a curious reader with little or no background in science, medicine, the drug industry or finance. General terms are explained once in the glossary. All money figures are in US dollars (USD). Every fact carries one of three tags. [VERIFIED — source] means a primary source confirmed it, and the source is named. [UNVERIFIED] means it could not be confirmed. [WEB ESTIMATE — source, date] means it is a third-party figure or a labelled model.

Program analyses for this company are the sub-folders listed in C.2.

Why the company tier was re-run. The previous company sweep was dated 2026-08-19, 59 days before this one. 02-connectors.md § Company-sweep currency allows reuse for 30 days only. A material event also landed in the press feed since then: the FDA feedback of 2026-09-22 (C.7). So every company-tier row below was called again on 2026-10-17. This version replaces the 5.10.3 document and keeps its corrections and audit trails, marked where they still apply.

C.0 Company-tier coverage — CLEARED

Every mandatory company-tier row was called. The regulatory tier is not part of this table. It is conditional on a regulatory catalyst (02-connectors.md § Regulatory tier), and the catalyst analysed under this ticker is a congress presentation. No marketing application has been filed.

ToolStateNote / verbatim error
BPIQ fetch_company_infoCALLEDfinance_updated_at 2026-06-30, so cash and burn are quarter-end figures. last_price 0.86 and previous_close 0.90 match the price cache’s 2026-10-16 and 2026-10-15 closes. market_cap and max_52_week_position reconcile this time (C.8 row 1). enterprise_value does not (C.8 row 2).
BPIQ fetch_company_drugsCALLED6 rows, every one in C.2. Three carry has_catalyst: true. Names stay dirty ("Tovecimig (CTX-009) …" has a double space), so every row is keyed on the integer id. The tovecimig row’s note gained a 2026-09-22 entry: “FDA advised survival-benefit trial before BLA; company will further engage FDA. ESMO data Oct 24, 2026.”
BPIQ fetch_company_historical_catalystsCALLEDCalled as fetch_all_historical_catalysts filtered to tickers: ["CMPX"], the connector’s current name for this row. 8 rows, one new (2026-09-22). Every row was re-checked against the price cache, which did not exist at the last sweep. Several BPIQ move fields do not reproduce from the cache (C.7 and C.8 row 3).
BPIQ fetch_company_options_dataCALLEDdate_updated 2026-10-17, 9 expiries. No strike sits at the $0.86 spot; the nearest are $0.50 and $1.00. Both implied-volatility artifacts are present. See C.6.
BPIQ fetch_company_insider_transactionsCALLEDReturned no rows on three attempts (immediate, retry, and again about ten minutes later), with no error. Two Form 4 filings exist in the window (EDGAR, 2026-09-25 and 2026-10-02). So the silent empty-result bug 02-connectors.md records on TLSA and CNTB now fires on this ticker. It did not fire on 2026-08-19, when the same call returned 113 rows. Insider flow in C.5 is read from EDGAR.
BPIQ fetch_company_press_releasesCALLED221 items, the newest dated 2026-10-14. Used for the same-day checks in C.7 and the delivery record in C.1a. Two GlobeNewswire originals (2026-09-22 and 2026-10-14) returned HTTP 403 to a direct fetch. The 2026-09-22 text was read from its SEC copy instead (8-K exhibit 99.1).
optional BPIQ fetch_company_hedge_fund_holdingsCALLED19 blocks, 2022Q2 to 2026Q3. No block is newer than at the last sweep. Labels confirmed as filing quarters against the price cache (C.8 row 6).
optional BPIQ fetch_company_earnings_transcriptNOT CALLEDOptional row. The latest call (second quarter, 2026-08-06) predates the FDA feedback, so it could not speak to the event that moved the shares.
EDGAR submissionsCALLEDCIK 0001738021. Filings since 2026-08-19: an 8-K on 2026-09-22 (items 7.01 and 9.01, the FDA update) and two Form 4s. No 8-K item 3.01 (a listing-deficiency notice), no proxy proposing a reverse split, and no new S-3 or 424B5 (a share sale).
EDGAR XBRL companyconcept (dei:EntityCommonStockSharesOutstanding)CALLED180,087,915 shares at 2026-07-28, from the 10-Q filed 2026-08-06. No later filing reports a count. The companion companyfacts call supplied cash, marketable securities, operating cash flow, options outstanding and total liabilities (C.3, C.4).
FINRA consolidatedShortInterestCALLEDSettlements 2026-07-31 to 2026-09-30 returned. The newest is 2026-09-30: 40,357,710 shares short, average daily volume 6,449,901, days-to-cover 6.26. The 2026-10-15 settlement returned empty, which is FINRA’s normal two-week publication lag.
optional Yahoo options chainNOT CALLEDOptional row. BPIQ’s chain is dated the sweep day and already shows that no strike sits at spot, which settles C.6 by itself. (Yahoo’s daily chart was called once, as a price cross-check. That is not this row. See C.8 row 4.)

C.1 What the company is

Compass Therapeutics is a clinical-stage cancer company in Boston, Massachusetts, founded in 2014. It makes antibody drugs, which are proteins engineered to stick to a chosen target on or around a tumour [VERIFIED — BPIQ fetch_company_info 2026-10-17]. It runs four molecules across the six pipeline rows in C.2. It has no approved product and no product revenue. Its 2025 revenue was nil, and its only past revenue was $850 thousand of licence income in 2024 from its Chinese partner [VERIFIED — Form 10-K for 2025, filed 2026-03-05].

In practice it is close to a single-asset company. One molecule, tovecimig (also called CTX-009), carries the only finished randomised trial and the only planned marketing application. On 2026-09-22 the FDA recommended a new trial showing a survival benefit before that application is filed (C.7). The shares now trade at about the company’s cash (C.4). That means the market currently assigns close to nothing to tovecimig or to the three earlier molecules.

Tovecimig is licensed, not owned. Compass took an exclusive global licence, excluding South Korea, from the South Korean company ABL Bio in November 2018. ABL Bio is owed tiered single-digit royalties on net sales and up to $96 million of development and regulatory milestones plus up to $303 million of commercial milestones in cancer [VERIFIED — Form 10-Q filed 2026-08-06, note 11]. South Korean rights sit with Handok. Compass out-licensed China to Elpiscience [VERIFIED — Form 10-K for 2025]. Named correction: the 5.10.3 version called these licence terms an unverified web estimate. They are now read from the filings, and they match.

C.1a Delivery record and capabilities

Program documents cite this section: A.5 uses the first two rows, M.4 the manufacturing rows and B.4d the last two. The milestone rows are read from the BPIQ note field (a dated log of the company’s own guidance) and checked against the press feed and EDGAR. Search date 2026-10-17.

ItemFindingSource / tag
Milestones met(1) COMPANION-002 enrolment completed 2024-08-06. (2) CTX-10726 IND filing guided for the fourth quarter of 2025; cleared by 2026-03-05 (an IND, an investigational new drug application, is the FDA filing that lets a trial start). (3) CTX-8371 Phase 1 data guided for the first half of 2026; poster at ASCO in May 2026. (4) FDA feedback on COMPANION-002 guided for the third quarter of 2026; announced 2026-09-22. (5) ESMO oral slot announced 2026-07-17 for 2026-10-24, unchanged since.[VERIFIED — BPIQ fetch_company_drugs note field 2026-10-17; EDGAR 8-K 2026-09-22]
Milestones missed or moved(1) COMPANION-002 topline guided “by the end of Q1 2025”; reported 2025-04-01, one day late. (2) Overall-survival data guided for the first quarter of 2026; reported 2026-04-27, about four weeks late. (3) The marketing application (BLA, Biologics License Application) was guided for the second half of 2026; it has not been filed, and the FDA has recommended a survival trial first. Secondary reports say the company now targets the first quarter of 2027. That date is not in the 2026-09-22 release or any filing. (4) The CTX-471 Phase 2 start has been re-guided five times (second half of 2025, then Q1 2026, mid-2026, second half of 2026, Q3 2026). The trial (NCT07684170) is registered but was “not yet recruiting” on 2026-10-17, after the Q3 deadline passed. (5) CTX-10726’s first patient was guided for the first quarter of 2026; the registry shows a start on 2026-05-28.[VERIFIED — BPIQ note field 2026-10-17; CT.gov NCT07684170 and NCT07419841, read 2026-10-17]; Q1 2027 BLA [WEB ESTIMATE — Stocktwits and aggregated coverage, 2026-09-23]
Own manufacturing sitesNone. “We do not currently own or operate manufacturing facilities for the production of clinical quantities of our product candidates.”[VERIFIED — Form 10-K for 2025, Business, Manufacturing]
Contract manufacturersThird-party contract development and manufacturing organisations (CDMOs). None is named in the 10-K, the 10-Q or the press feed. The second-quarter 10-Q shows $7.5 million of accrued manufacturing expense, mostly for tovecimig, and lists “registration and validation batches” among manufacturing costs. No public record names the site as of 2026-10-17.[VERIFIED — Form 10-K for 2025; Form 10-Q filed 2026-08-06]
Launch experience and sales forceNo drug launched. No sales force. 39 employees at 2025-12-31, 25 of them in research and clinical work. A Chief Commercial Officer joined 2026-01-05. A new hire received 200,000 inducement options at $0.86 on 2026-10-14.[VERIFIED — Form 10-K for 2025; press feed 2026-01-05]; 2026-10-14 grant [WEB ESTIMATE — BiopharmaWatch reproduction of the GlobeNewswire release, 2026-10-14]
Partnerships and licences(1) ABL Bio, November 2018: tovecimig in-licence, terms in C.1; ABL Bio has received $5 million upfront and a $6 million milestone. (2) Handok: holds South Korea. (3) Elpiscience: China out-licence; paid a $1 million milestone in 2024, of which 15% passes to ABL Bio. (4) Adimab, 2014: antibody discovery, single-digit royalties. (5) Investigator-sponsored trials at MD Anderson (first-line BTC) and Washington University (colorectal, glioblastoma). No partner shares tovecimig’s US economics.[VERIFIED — Form 10-K for 2025; Form 10-Q filed 2026-08-06]

C.2 Pipeline — every program

Every row returned by fetch_company_drugs on 2026-10-17 is listed. “Date to a day?” is yes only where catalyst_date_text names a day (01-rules.md rule 23). Every “no” row carries a BPIQ period-end placeholder in catalyst_date. No timing anywhere in this repository uses it.

Program (drug — indication)bpiq_drug_idStage & eventCatalyst (as disclosed)Date to a day?Analysed?Materiality to the stock
Tovecimig (CTX-009), DLL4 × VEGF-A bispecific antibody — biliary tract cancer17398Phase 2/3 Data readout”October 24, 2026”YesYes — tovecimig-biliary-tract-cancer/Dominant. The only late-stage asset and the only planned marketing application. Its two 2026 events produced the two largest moves in C.7 (−64.6% and −35.2% over the protocol’s event window). With the shares at the cash floor (C.4), any re-rating of the company runs through this program.
Tovecimig (CTX-009) — colorectal cancer17399Phase 2 Update”TBA”NoNoImmaterial. has_catalyst is false. COMPANION-003 did not advance in November 2024. The row now tracks an investigator-sponsored Phase 2 (NCT07662031, Washington University, 25 patients) that the 2026-08-06 release says has been initiated. Nothing datable.
Tovecimig + CTX-471 — glioblastoma20762Phase 2 Initiation”TBA”NoNoImmaterial. has_catalyst is false. An investigator-sponsored Phase 1b/2 (NCT07392957, 54 patients) with a 2029 primary completion date.
CTX-471 ± pembrolizumab (KEYTRUDA) — NCAM-positive tumours17478Phase 2 Initiation”Q3 2026”NoNoImmaterial. has_catalyst is false. A trial start, not data. The Q3 2026 date has passed with no start announced, and NCT07684170 is registered as not yet recruiting.
CTX-8371, PD-1 × PD-L1 bispecific antibody — solid tumours17481Phase 1 Data readout”Q4 2026”NoNoMeaningful. Expansion-cohort data are guided for Q4 2026 after an ASCO 2026 poster with responses and no dose-limiting toxicities. With tovecimig’s filing in doubt, a larger share of the remaining value sits here. Its “Q4 2026” window covers tovecimig’s disclosed day, so it is one of the two conflicts that make that program CONTAMINATED.
CTX-10726, PD-1 × VEGF-A bispecific antibody — solid tumours18722Phase 1 Data readout”Q4 2026”NoNoMeaningful but speculative. First patients were dosed in 2026 (NCT07419841, started 2026-05-28). Initial data are guided for Q4 2026. PD-1 × VEGF bispecifics are a crowded and fashionable class, which makes a signal valuable and a thin one easy to dismiss. The second conflict inside the tovecimig window.

Three rows carry has_catalyst: true and all three fall in the fourth quarter of 2026. One of the three dates is disclosed to a day. So the collision the program document’s Attribution section describes is a real feature of this pipeline, not two placeholders touching.

C.3 Financial position

ItemValueAs ofTag
Cash and equivalents$35.453M of cash and equivalents; $179.879M with marketable securities ($144.426M)2026-06-30[VERIFIED — EDGAR XBRL CashAndCashEquivalentsAtCarryingValue and MarketableSecuritiesCurrent, 10-Q filed 2026-08-06]
Burn (per month)$4.913M (second quarter); $5.335M (first-half average)quarter to 2026-06-30[VERIFIED — EDGAR XBRL NetCashProvidedByUsedInOperatingActivities: −$32.007M for the half, −$17.269M for the first quarter, so −$14.738M for the second]
Runway as the company states it”into 2028”2026-08-06[VERIFIED — Form 10-Q filed 2026-08-06]. Not restated after the FDA feedback: the 2026-09-22 8-K gives no runway.
Runway recomputed (cash ÷ burn)36.6 months, to about mid-20292026-06-30[UNVERIFIED — computed] $179.879M ÷ $4.913M a month
DebtNone2026-06-30[VERIFIED — EDGAR XBRL companyfacts: no debt concept reported; total liabilities $24.124M, mostly accrued expenses and an office lease]

The company’s runway is the one to use, as in the 5.10.3 version. “Into 2028” implies a burn well above the second-quarter rate, which fits a company building toward a launch. The FDA recommendation may change that plan in either direction: a survival trial costs money, while a delayed launch saves commercial spending. The company has not said which. BPIQ’s screening text once carried a runway to 2029-01-08. It is empty this sweep and was never used.

Dilution history.

DateInstrumentGross proceedsPriceSource
2025-08-12Underwritten public offering: 33,290,000 shares and 6,710,000 pre-funded warrants (warrants paid for upfront, exercisable at $0.0001), plus 6,000,000 option shares the underwriters bought$138.0M ($120.0M base plus $18.0M option)$3.00 a share; $2.9999 a pre-funded warrant[VERIFIED — Form 10-Q filed 2026-08-06, equity note; 424B5 filings 2025-08-12 and 2025-08-13]
2025-12-30Form S-3 shelf of up to $400M, including an at-the-market (ATM) programme of up to $100M with Leerink Partners and Cantor Fitzgerald. An ATM sells new shares gradually into the market.Nil to 2026-06-30: “we did not sell any shares”n/a[VERIFIED — S-3 filed 2025-12-30, EFFECT 2026-01-07; Form 10-Q filed 2026-08-06]
2026-03-12Form S-8 (registers shares for employee plans)Nil, not a raisen/a[VERIFIED — EDGAR submissions]

No offering was announced and then withdrawn. Named correction: the 5.10.3 version put the August 2025 raise at $120M and derived an implied $3.03 a share. The 10-Q shows $138.0M gross at $3.00, because the underwriters also bought 6,000,000 option shares.

A raise before the 2026-10-24 presentation is unlikely. Selling shares at about cash value would dilute holders for little money. The ATM capacity is unused and the public float is worth about $136M, above the $75M line below which the SEC limits shelf sales. So a sale is possible at any time after the event, and most likely into any strength it produces.

C.4 Valuation frame

ItemValueSource / tag
Share price (spot)$0.86, the settled close of Friday 2026-10-16[VERIFIED — data/prices/CMPX.json via lib/prices.mjs closeOnOrBefore, fetched 2026-10-17 after the close; matches BPIQ last_price 0.86 and Yahoo's daily close]
Market capitalisation$154.9M[UNVERIFIED — computed] 180,087,915 filed shares × $0.86. BPIQ’s $154,875,616 agrees.
Enterprise value−$25.0M against 2026-06-30 cash; about −$10.3M against an estimated 2026-09-30 cash of $165.1M[UNVERIFIED — computed] $154.9M − $179.879M; the 2026-09-30 cash is extrapolated at the second-quarter burn and is not reported. BPIQ’s $40,456,860 is not used (C.8 row 2).
52-week high / low$6.88 (2026-02-03) / $0.822 (2026-10-14)[VERIFIED — data/prices/CMPX.json, lib/prices.mjs range52w as of 2026-10-16]
Position in the 52-week range, computed off the last price0.6%[UNVERIFIED — computed] lib/prices.mjs positionInRange(0.86, 0.822, 6.88) = 0.00627. BPIQ’s 0.00627 agrees.
Multiple off the 52-week low1.05×[UNVERIFIED — computed] $0.86 ÷ $0.822
Economic share count186,797,915[VERIFIED — XBRL dei:EntityCommonStockSharesOutstanding 180,087,915 at 2026-07-28, plus 6,710,000 pre-funded warrants outstanding per the 10-Q filed 2026-08-06]

This row is the run-up baseline for every program under this ticker. The shares sit at the bottom of a range whose top was set on 2026-02-03, before both 2026 tovecimig events. They closed below $1 on 11 of the 12 sessions since 2026-10-01. Only 2026-10-07 ($1.02) closed above.

Listing compliance, and why it does not touch the per-share figures. Nasdaq gives notice of a deficiency after 30 consecutive business days with a closing bid below $1.00 (Listing Rule 5550(a)(2)). The company then has 180 days to recover, often followed by a reverse split, which merges shares and multiplies the price [UNVERIFIED — rule summary, not read from the rulebook this sweep]. The current run began on 2026-10-08: seven business days by 2026-10-16. So no notice can arrive before about 2026-11-19, and no notice is on EDGAR. The June 2026 annual meeting voted on directors, the auditor and pay only [VERIFIED — 8-K filed 2026-06-11, item 5.07]. No reverse split is authorised, so none can land inside this event’s settlement window. Every per-share figure here is on the current share count.

Economic share count. Common shares (180,087,915) plus pre-funded warrants (6,710,000) gives 186,797,915. No warrant or option is in the money at $0.86. The 23,650,088 options outstanding at 2026-06-30 carry a weighted average exercise price of $3.87, and the 200,000 options of 2026-10-14 were struck at $0.86 itself [VERIFIED — XBRL companyfacts; 10-Q filed 2026-08-06]. The 1,606,250 unvested restricted stock units are not options and are left out, as the rule defines the count. Named correction: the 5.10.3 version divided its cash per share by the reported 180,087,915 shares and missed the pre-funded warrants.

C.5 Ownership and flow

Holder typeShareNoteSource
Insider12.47%Includes the OrbiMed / Carl Gordon 10%-owner position, reported both as a fund and as a director[VERIFIED — BPIQ fetch_company_info 2026-10-17, insider_own 0.12467]
Institutional88.56%Overlaps the insider figure; the two are not additive[VERIFIED — BPIQ fetch_company_info 2026-10-17, tute_own 0.88559]
Retail / otherNot separately reportedThe two figures above sum above 100%, so no residual can be derived[UNVERIFIED]
Short interest40,357,710 shares = 22.4% of shares outstanding, or 25.6% of the estimated non-affiliate float (157.6M shares); days-to-cover 6.26Settlement 2026-09-30. It peaked at 41,647,512 on 2026-09-15 and eased 3.1% after the FDA news.[VERIFIED — FINRA consolidatedShortInterest, settlement 2026-09-30, divided by the EDGAR-filed share count]

Short interest by settlement [VERIFIED — FINRA consolidatedShortInterest, read 2026-10-17]:

SettlementShares shortAverage daily volumeDays to cover
2026-07-3139,874,2502,263,27617.62
2026-08-1440,197,9384,110,6009.78
2026-08-3140,788,8912,362,77717.26
2026-09-1541,647,5122,605,17415.99
2026-09-3040,357,7106,449,9016.26

Days to cover fell because volume tripled after the FDA news, not because shorts closed. The short count barely moved.

Insider flow: the first open-market buying since April, and it is small. The chief accounting officer, Neil Lerner, bought 2,500 shares at $1.14 on 2026-09-24 and 20,000 shares at $0.92 on 2026-10-01. Both are transaction code P, an open-market purchase. Together they cost about $21,250 and took his holding to 420,000 shares, of which 62,500 are unvested restricted stock units [VERIFIED — EDGAR Form 4s filed 2026-09-25 and 2026-10-02]. No other officer or director has filed a Form 4 since 2026-04-30. One officer buying a small amount is a gesture. The silence of every other insider at about cash value is the larger fact.

Concentration is high, and no new register is visible yet. The newest 13F block (the quarterly filing in which large funds disclose holdings) is labelled 2026Q3 and holds positions at 2026-06-30. It is the same block the last sweep read. The six funds in it are Tang Capital (17.99M shares), OrbiMed (15.22M), Vivo (7.76M), Palo Alto Investors (5.83M), ADAR1 (0.12M) and Ikarian (18,000) [VERIFIED — BPIQ fetch_company_hedge_fund_holdings 2026-10-17, share counts]. Together they hold about 46.9M shares, roughly a quarter of the company. How they traded through the 2026-09-22 news will show in 13Fs due by 2026-11-14. EDGAR also shows a State Street Schedule 13G (a filing by a passive holder of more than 5%) dated 2026-08-07, reported at 9.95M shares [WEB ESTIMATE — Stock Titan summary of the 13G, 2026-08-11].

The law-firm “investigation” announcements of April to July 2026 were not followed by any filed complaint visible in EDGAR or the press feed [VERIFIED — EDGAR submissions and press feed, 2026-10-17].

C.6 Options chain and its readability

Plain takeaway: the chain cannot price this event. No strike sits at the $0.86 spot. The nearest are $0.50 and $1.00, and the quotes around them are too wide to read a price from. Two positions stand out. An open interest of 60,014 contracts sits on the January 2027 $1.00 put, which covers about 6 million shares. And 23,664 contracts of the November $3.00 call remain from the August speculation, now far out of the money. Neither says what the market expects from the 2026-10-24 presentation.

ItemValueNote
Spot$0.86C.4
Nearest listed strike to spot$0.50 below, $1.00 above; nothing betweenThe $1.00 strike sits 16% above spot.
Expiry nearest the next catalyst2026-11-20, the first expiry after the 2026-10-24 presentationThe 2026-10-16 expiry has passed.
At-the-money straddle ÷ spotNot computableA straddle (a call and a put at the strike nearest spot) can only be bracketed at $1.00 on the 2026-11-20 expiry. At mid prices it costs $0.45, or 52% of spot. The bid side gives $0.25 (29%) and the ask side $0.65 (76%). A range that wide is not a price.
Front implied volatility2.53 ($1.00 call) and 1.24 ($1.00 put), 2026-11-20 expiryBoth are off the BPIQ floor (~0.01488) and ceiling (~9.99512) artifacts. Several other strikes sit on one artifact or the other and are treated as missing. The call and put at the same strike disagree by a factor of two, which says the quotes are not trading prices.
Open interest at that strike$1.00 call 2,700; $1.00 put 1,334 (2026-11-20)5,385 of the $1.00 calls traded in the last session.
Liquidity confidenceLowNo strike at spot, spreads of 100% or more, and contradictory implied volatility.

The program document therefore takes its move range from the ticker’s own history and a stated calibration, not from this chain.

C.7 Reaction to past catalysts

How to read the two move columns. The BPIQ columns are the connector’s own fields. The event-window column is computed from the price cache with the window 05-prediction-protocol.md uses at settlement: the average of the two closes before the announcement day, against the average of the announcement-day close and the next day’s close. The cache did not exist at the last sweep. It now shows that several BPIQ figures cannot be reproduced (C.8 row 3). The event-window column is the one the program document’s anchors read.

DateEventBPIQ intraday / open gapEvent window (cache)Same-day press-feed checkRead
2026-09-22FDA recommended a trial showing a survival benefit before a BLA for tovecimig in previously treated biliary tract cancer−0.80% / −31.32%−35.2% (close to close −31.9%, $1.82 → $1.24, on 27.2M shares, about eleven times normal volume)The company’s release the same morning (8-K exhibit 99.1). The next day, Wedbush cut to Neutral with a $1 target (from $5), and other brokers cut too. No offering, no other program news.A regulatory event, and clean. The gap is the move, as on 2026-04-27. The shares kept falling for nine more sessions, to $0.857 on 2026-10-02, and have stayed below $1 since.
2026-04-27COMPANION-002 secondary endpoints: progression-free survival met (4.7 vs 2.6 months, hazard ratio 0.44); overall survival not met (8.9 vs 9.4 months, hazard ratio 1.05)+1.13% / −64.81%−64.6% (close to close −64.4%, $5.03 → $1.79, on 159.0M shares)Six same-day items describing a collapse, plus two law-firm solicitationsThe gap is the move; the intraday figure is not. Kept from the 5.10.3 version, and now confirmed by the cache. The market punished a secondary-endpoint miss on a trial whose primary endpoint had already been met.
2025-04-21First patient dosed in an investigator-sponsored first-line trial+8.72% / −1.71%+9.0% (close to close +1.7%)The announcement itselfAdministrative. More plausibly drift from the weeks after 2025-04-01 than a reaction to the dosing.
2025-04-01COMPANION-002 met its primary endpoint (overall response rate)+49.73% / −1.58%+1.0% (close to close +17.9%, $1.90 → $2.24; the next day fell to $1.69)Two same-day items, both the endpoint announcementNamed correction. The 5.10.3 version read the +49.73% as “roughly doubled the shares” and used it as the upper bound for tovecimig news. The cache shows a day that opened at $1.87, fell to $1.33 and closed at $2.24. The +49.73% matches none of the cache’s open-to-close (+19.8%), close-to-close (+17.9%) or low-to-close (+68.4%) moves for that day. Over the event window the hit was worth +1.0%, because the next session gave the gain back.
2024-11-08CTX-471 Phase 1 biomarker data at the Society for Immunotherapy of Cancer meeting+4.28% / +1.63%+0.8% (close to close −2.2%)The announcement itselfThe nearest comparable in kind to the 2026-10-24 event: a congress presentation of data already described. Over the window it moved +0.8%. The BPIQ figure does not reproduce.
2024-08-12COMPANION-003 colorectal Phase 2 data, released with second-quarter results+7.14% / +2.75%+11.0% (close to close +3.7%)The same-day earnings release carried the dataBundled with earnings, so not cleanly attributable.
2024-04-16First patient dosed, CTX-8371 Phase 1+8.86% / 0.00%−3.1% (close to close −0.6%)The announcement itselfAdministrative.
2024-04-09Preclinical CTX-009 + CTX-471 data at the American Association for Cancer Research meeting+8.28% / −0.59%−3.8% (close to close −1.8%)A third-party (Synapse) summary, not a company releasePreclinical. Recorded for completeness.

What the table says as a whole. Read from the cache, this ticker’s data events in 2024–2025 moved it very little over the event window: +1.0%, +0.8% and +11.0% on its positive data rows. Its two 2026 tovecimig events were hypothesis-level news (a survival endpoint and an FDA position), and each removed a third to two-thirds of the price. The 2026-10-24 event is a presentation of data whose headline figures are already public. The 5.10.3 version drew the same distinction. It also leaned on a +49.7% upside figure that the cache now shows was never a two-day move.

C.8 Company data-quality flags

  1. market_cap and max_52_week_position reconcile on this sweep, and the earlier failure is kept as history. On 2026-08-19 both fields were computed off the previous close (5.10.3 C.8 rows 1 and 2). On 2026-10-17, a Saturday, last_price equals the last close. BPIQ’s $154,875,616 equals 180,087,915 × $0.86, and its 0.00627 equals the cache’s position. The bug cannot be seen when the last price and the last close are the same price, so this sweep does not show it was fixed.
  2. enterprise_value cannot be reconciled. BPIQ’s $40,456,860 against its own $154,875,616 market cap implies subtracting $114.4M. Its own cash field is $179.879M. No reported cash figure at any recent quarter-end is $114.4M (2025-12-31: $208.9M; 2026-03-31: $194.7M; 2026-06-30: $179.9M). C.4 recomputes.
  3. BPIQ’s historical-catalyst move fields do not reproduce from the price cache on most CMPX rows. The 2025-04-01 row’s +49.73% “intraday” figure matches no open-to-close, close-to-close or low-to-close move in the cache. The 2024-11-08 row’s +4.28% sits against a cache day that closed below its open. The rows created on 2025-02-21 all carry news_published_at 2025-02-15, which suggests their price fields were computed from a different day. C.7 shows the BPIQ figures beside the cache’s event-window figures and uses the cache.
  4. The price cache froze an intraday bar on 2026-08-19, the day of the last lock. The stored bar reads close $2.42 on 1,160,393 shares. Yahoo’s daily chart gives a settled close of $2.48 on 3,903,300 shares (checked 2026-10-17). This is the failure scripts/fetch-prices.mjs is known for: it never overwrites a bar first written mid-session. The 5.10.3 record’s spot of $2.48 matches the settled close. The cache does not. data/prices/ is outside this analysis’s lane, so the bar is reported here and not corrected. The 2026-10-16 bar this lock uses ($0.86 on 2,038,900 shares) matches Yahoo’s settled figures.
  5. fetch_company_insider_transactions returned zero rows on three attempts while two Form 4s exist. This is the connector-wide bug 02-connectors.md documents. It is now confirmed on a third ticker, and on a ticker where the same call had worked eight weeks earlier. C.5 reads the flow from EDGAR.
  6. 13F block labels are filing quarters on this ticker, now confirmed against the cache. Value ÷ shares gives $2.19 for the 2026Q3 block, $5.29 for 2026Q2 and $5.37 for 2026Q1. Those equal the cache closes of 2026-06-30 ($2.19), 2026-03-31 ($5.29) and 2025-12-31 ($5.37). Each block holds positions one quarter older than its label. The 5.10.3 version reached this from the implied prices alone, because the cache did not exist then.
  7. short_float disagrees with FINRA, and the 5.10.3 explanation is withdrawn. BPIQ reports 0.30476, dated 2026-09-30. FINRA’s 2026-09-30 count is 22.4% of shares outstanding or 25.6% of the non-affiliate float. The 5.10.3 version suggested a rising count might explain BPIQ’s 0.30106 at 2026-07-31. FINRA’s 2026-07-31 settlement, readable this sweep, shows 39,874,250 shares, 22.1% of shares outstanding. So rising short interest does not explain the gap. BPIQ’s figure implies a denominator of about 132M shares, which matches no float this sweep can derive.
  8. The note field is a dated slip log on four of six rows. CTX-471’s Phase 2 start has now missed five guided dates. The tovecimig row’s slips are counted in the program document.
  9. A “Revenue ($25.25M)” figure circulates in third-party summaries of the second-quarter 10-Q, and it stays rejected under 01-rules.md rule 6. Kept from 5.10.3. Compass has no product. The 10-Q’s quarterly net loss is $25.154M, and the summariser mislabelled a loss line as revenue.
  10. Analyst targets conflict, and none is an anchor under 6.2.0. Kept from 5.10.3: one aggregator’s $14.57 average and $30 high were stale pre-April targets. After 2026-09-22, Wedbush moved to $1 from $5, Guggenheim to $4 and H.C. Wainwright to $12 from $24 [WEB ESTIMATE — Seeking Alpha, MarketScreener and Stocktwits coverage, 2026-09-23]. 01-rules.md rule 30 bars analyst targets from scenario anchors. They are recorded here so that a reader who meets them knows they were seen.
  11. Two GlobeNewswire originals returned HTTP 403 to a direct fetch (2026-09-22 and 2026-10-14). The first was read from its SEC copy. The second, the 200,000-option inducement grant, rests on a secondary reproduction only.

Sources

    BPIQ fetch_company_info, fetch_company_drugs, fetch_all_historical_catalysts (tickers CMPX), fetch_company_options_data, fetch_company_insider_transactions (x3, empty), fetch_company_press_releases, fetch_company_hedge_fund_holdings - all 2026-10-17 EDGAR submissions CIK 0001738021, read 2026-10-17; 8-K filed 2026-09-22 with exhibit 99.1; Form 4s filed 2026-09-25 and 2026-10-02; 8-Ks filed 2026-06-11 and 2026-06-23; S-3 filed 2025-12-30 EDGAR XBRL companyconcept dei:EntityCommonStockSharesOutstanding and companyfacts (cash, marketable securities, operating cash flow, options, liabilities), read 2026-10-17 Form 10-Q for the quarter to 2026-06-30, filed 2026-08-06; Form 10-K for 2025, filed 2026-03-05 FINRA consolidatedShortInterest, settlements 2026-07-31 to 2026-09-30, read 2026-10-17 data/prices/CMPX.json via lib/prices.mjs (fetched 2026-10-17); Yahoo Finance daily chart cross-check for 2026-08-19 and 2026-10-16 CT.gov NCT07684170, NCT07419841, NCT07662031, NCT07392957, read 2026-10-17